Oncosil Medical (OSL) investor relations material

Executive summary

• Achieved 60% year-over-year growth in dose sales and 49% increase in revenue for Q3 FY26, with commercially active treatment centres up 56% to 28 compared to Q3 FY25.

• Expanded clinical adoption in Europe and Türkiye, with strong early clinical results and new hospital partnerships.

• Advanced key clinical trials (TRIPP-FFX, PANCOSIL) and prepared for the fully funded G-BA trial in Germany, expected to commence in Q4 FY26.

• Completed $8 million capital raise and ended the quarter with $9.3 million in cash, supporting ongoing operations and growth initiatives.

Financial highlights

• Customer receipts for Q3 FY26 were $0.6 million, up 158% year-over-year; nine-month receipts totaled $1.7 million, up 177%.

• Operating cash outflows decreased to $1.0 million from $2.1 million in the prior quarter, aided by a $1.8 million R&D tax incentive.

• Cash and cash equivalents at 31 March 2026 were $9.3 million, up from $2.9 million at 31 December 2025.

• Completed $8 million capital raise during the quarter.

Outlook and guidance

• TRIPP-FFX trial results expected in FY26 to support broader adoption and label expansion.

• Regulatory submission for percutaneous application and label expansion to include FOLFIRINOX planned for FY26 and 1H FY27.

• First commercial dose supply from new Sydney manufacturing facility expected in 1H FY27, aiming to reduce COGS and support growth.

• Anticipated initiation of the G-BA trial in Germany in FY26, a major milestone for market access.